Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Cancer Research
|
November 24, 2001
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
B P Rubin, S Singer, C Tsao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 14, 2009
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S George, J Y Blay, P G Casali, et al.
Oncogene
|
April 16, 2013
Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors
A Mariño-Enríquez, W-B Ou, G Cowley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 8, 2018
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
R L Jones, G D Demetri, S M Schuetze, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 7, 2011
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
A Gronchi, B N Bui, S Bonvalot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2005
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study
R Garcia-Carbonero, J G Supko, R G Maki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 3, 2016
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy
E Ben-Ami, C M Barysauskas, M von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 16, 2004
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
R Garcia-Carbonero, J G Supko, J Manola, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2012
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy
N Penel, G D Demetri, J Y Blay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2005
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO
J-Y Blay, S Bonvalot, P Casali, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Cancer Research
|
November 24, 2001
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
B P Rubin, S Singer, C Tsao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 14, 2009
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S George, J Y Blay, P G Casali, et al.
Oncogene
|
April 16, 2013
Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors
A Mariño-Enríquez, W-B Ou, G Cowley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 8, 2018
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
R L Jones, G D Demetri, S M Schuetze, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 7, 2011
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
A Gronchi, B N Bui, S Bonvalot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2005
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study
R Garcia-Carbonero, J G Supko, R G Maki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 3, 2016
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy
E Ben-Ami, C M Barysauskas, M von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 16, 2004
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
R Garcia-Carbonero, J G Supko, J Manola, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2012
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy
N Penel, G D Demetri, J Y Blay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2005
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO
J-Y Blay, S Bonvalot, P Casali, et al.
Page
of 7